Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Claritin Patent Infringement Suit Brings Industry Into OTC Antihistamine Fray

This article was originally published in The Tan Sheet

Executive Summary

Schering-Plough's lawsuits against McNeil Consumer Healthcare and Whitehall-Robins could at least temporarily relieve FDA of having to make a highly charged public policy decision on whether to advocate a forced switch of second-generation antihistamines

Related Content

“Paper NDAs”
Wyeth OTC loratadine “approvable”
Wyeth loratadine deal
Claritin patent litigation
Wyeth Children’s Advil Cold Combination Suspension Extends Pediatric Line
Allegra, Zyrtec Will Not Follow Claritin OTC In Near Future, Execs State
OTC Claritin Hatch/Waxman Exclusivity Not Expected By Schering-Plough
OTC Allegra Filing Possibility Prepared For By Aventis – CEO
Thompson on antihistamine switches
OTC Sale Of Rx Allergy Drugs Would Be Safer, Cut Costs - Health Plan





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts